Denali Therapeutics Inc. (DNLI) has a consensus analyst rating of Buy, based on 17 analysts covering the stock. Of those, 17 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for DNLI is $34.40, representing a +70.6% upside from the current price of $20.16. Price targets range from a low of $25.00 to a high of $40.00.
